Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance -- Updat..
01/07 ALNYLAM PHARMACEUTICALS : Sanofi Restructure RNAi Rare-Disease Alliance
01/05 Best week since April for European shares as UK, Swiss indexes hit records
01/02 New drug approvals hit 21-year high in 2017
2017 U.S. tax cuts mix pleasure and pain for Europe's dollar earners
2017 STOCKS TO WATCH : CSX, Aclaris, Alnylam, Rigel
2017 ALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
2017 France's Sanofi pins hopes on new drugs after setbacks
2017 Sanofi investors hungry for drug progress and deal news
2017 Tax-loss selling to pressure 2017's losers in December
2017 GENMAB : and J&J 'love' partnership as some ponder takeover
2017 BIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
2017 Regeneron drops eye-drug combination as Novartis chases Eylea
2017 BAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
2017 U.S. FDA approves first two-drug HIV regimen in win for GSK
2017 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
2017 Recovery rally for European stocks leaves oil sector behind
2017 Poor earnings updates keep European shares at seven-week low
2017 NOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
2017 Prosecutors search Metro offices in insider trading probe
2017 As Experimental Treatments Grow, Families Face Tough Choices
2017 Pfizer expects broad interest for consumer health business
2017 SANOFI : and Regeneron Report Positive Asthma Trial Results
2017 MARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
2017 MARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
2017 MARKET SNAPSHOT : S&P 500, Nasdaq Climb After Stronger-than-expected GDP, Hot Te..
2017 GILEAD SCIENCES : Looks Away From Hepatitis C Treatments for Growth
2017 GlaxoSmithKline's new boss struggles to sell cure for drugmaker
2017 GILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
2017 GILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
2017 Regeneron-Sanofi drug succeeds mid-stage study
2017 Appeals Court Rules Against Amgen in Patent Case -- Update
2017 Appeals Court Rules Against Amgen in Patent Case
2017 Merck to stop development of hepatitis C treatments
2017 Lonza CFO sees in-house growth, not takeovers, to grow drug services
2017 SANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
2017 FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
2017 FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
2017 GILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
2017 GILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
2017 Gilead to buy Kite for promising cancer therapies in $12 billion deal
2017 GILEAD SCIENCES : The Promising New Cancer Treatment Behind Gilead's $11 Billion..
2017 Hot Stocks to Watch in the U.S. and Canada
Financials (€)
Sales 2017 66,8 M
EBIT 2017 -49,9 M
Net income 2017 -64,8 M
Finance 2017 157 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 36,6x
EV / Sales 2018 40,4x
Capitalization 2 602 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ABLYNX68.05%3 190
CELLTRION, INC.--.--%37 510
IQVIA HOLDINGS INC2.37%20 782
LONZA GROUP0.76%20 640
INCYTE CORPORATION-4.65%19 399
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 192
NEKTAR THERAPEUTICS16.21%11 048
ALKERMES PLC2.54%8 630
SYNEOS HEALTH INC-8.49%8 306
SEATTLE GENETICS, INC.-1.76%7 693
QIAGEN0.00%7 516
SAGE THERAPEUTICS INC1.21%6 844
IONIS PHARMACEUTICALS INC2.60%6 179
ICON PLC0.65%6 050
UNITED THERAPEUTICS CORPORATION-5.16%6 029
PRA HEALTH SCIENCES INC2.00%5 886
EXACT SCIENCES CORPORATION0.78%5 842
GALAPAGOS13.02%5 574
BIO-TECHNE CORP8.58%5 245
CHARLES RIVER LABORATORIES INTL. INC-2.45%5 052
BB BIOTECH AG6.04%3 962